Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 1, 2026
Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinomaGael S Roth, Jérôme Cros, Cindy Neuzillet, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2026
18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter StudyAlexandre Cochet, Victor Besson, Aurélie Bertaut, et al.
Molecular Cancer Therapeutics|October 24, 2015
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 StudySylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.
JHEP Reports : Innovation in Hepatology|July 28, 2026
Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort)Claire Noé, Julie Henriques, Brice Chanez, et al.
Clinics and Research in Hepatology and Gastroenterology|May 24, 2024
Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancerNicolas Cazeneuve, Olivier Bouché, Julie Leger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2021
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II StudyJean Marc Phelip, Jérôme Desrame, Julien Edeline, et al.
Plos One|September 19, 2018
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinibOlivier Bouché, Axel Le Cesne, Maria Rios, et al.
Cancer Medicine|November 17, 2022
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohortSylvain Manfredi, Marie Dior, Olivier Bouche, et al.
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Pageof 11